This trial is active, not recruiting.

Condition proliferative diabetic retinopathy
Sponsor Medical University of Silesia
Collaborator Department of Molecular Biology, Medical University of Silesia
Start date June 2012
End date September 2013
Trial identifier NCT01946451, SilesianMU


The purpose of this study was to investigate the expression of selected genes both in epiretinal membranes (ERMs) and peripheral blood mononuclear cells (PBMCs) from patients with primary and secondary epiretinal membranes in proliferative diabetic retinopathy. Possible correlations between messenger ribonucleic acid (mRNA) levels of these genes were also identified.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective retrospective

Primary Outcomes

Gene expression in patients with idiopathic and secondary epiretinal membranes in proliferative diabetic retinopathy.
time frame: The period between the diagnosis of the ERMs and the actual surgery for the condition was between 2 and 43 months.

Eligibility Criteria

Male or female participants at least 55 years old.

Inclusion Criteria: - Caucasian race, - both males and females, - aged ≥ 55 years, - suffering from idiopathic ERMs or secondary ERMs in proliferative diabetic retinopathy (PDR). - Presence of ERM was proven in optical coherence tomography (OCT) examination. Exclusion criteria: - aged < 55 years, - systemic connective tissue disease, - active inflammatory process

Additional Information

Official title Gene Expression and Their Correlations in Patients With Idiopathic and Secondary Epiretinal Membranes in Proliferative Diabetic Retinopathy
Trial information was received from ClinicalTrials.gov and was last updated in September 2013.
Information provided to ClinicalTrials.gov by Medical University of Silesia.